Trial Profile

Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sabizabulin (Primary) ; Dexamethasone; Remdesivir
Indications COVID-19 respiratory infection; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Sponsors Veru Healthcare

25 Apr 2022 According to a Verus Pharmaceuticals media release, Michael Gordon MD is lead investigator for this study.
25 Apr 2022 According to a Verus Pharmaceuticals media release, results from this were presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2022.
25 Apr 2022 Results published in the Verus Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com